| Pulmonary arterial hypertension
Tadliq vs Veletri
Side-by-side clinical, coverage, and cost comparison for pulmonary arterial hypertension.Deep comparison between: Tadliq vs Veletri with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsVeletri has a higher rate of injection site reactions vs Tadliq based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Veletri but not Tadliq, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Tadliq
Veletri
At A Glance
Oral
Once daily
PDE5 inhibitor
IV infusion
Continuous infusion
Prostacyclin
Indications
- Pulmonary arterial hypertension
- Pulmonary arterial hypertension
Dosing
Pulmonary arterial hypertension 40 mg (10 mL) once daily with or without food; start at 20 mg (5 mL) once daily in mild-to-moderate renal or mild-to-moderate hepatic impairment, increasing to 40 mg based on tolerability; avoid in severe renal impairment and severe hepatic impairment; when initiating TADLIQ in patients on ritonavir for at least one week, start at 20 mg once daily and increase to 40 mg based on tolerability; when starting ritonavir in patients already on TADLIQ, stop TADLIQ at least 24 hours prior and resume at 20 mg once daily after at least one week.
Pulmonary arterial hypertension Initiate continuous IV infusion at 2 ng/kg/min via central venous catheter; increase in increments of 2 ng/kg/min every 15 minutes or longer until tolerance limit established or further increases are not clinically warranted; adjust maintenance dose by 1- to 2-ng/kg/min increments at intervals of at least 15 minutes based on symptom persistence or adverse events.
Contraindications
- Concomitant use of any form of organic nitrate, either regularly or intermittently
- Concomitant use of guanylate cyclase (GC) stimulators such as riociguat
- Known serious hypersensitivity to tadalafil (TADLIQ, ADCIRCA, or CIALIS)
- Chronic use in patients with congestive heart failure due to severe left ventricular systolic dysfunction
- Pulmonary edema developing during dose initiation (associated with pulmonary veno-occlusive disease)
- Known hypersensitivity to epoprostenol or structurally related compounds
Adverse Reactions
Most common (>=9%) Headache, myalgia, nasopharyngitis, flushing, respiratory tract infection, pain in extremity, nausea, back pain, dyspepsia, nasal congestion
Serious Hypotension, visual loss, hearing loss, priapism
Postmarketing Serious cardiovascular events (myocardial infarction, sudden cardiac death, stroke, chest pain, palpitations, tachycardia), hypersensitivity reactions (urticaria, Stevens-Johnson syndrome, exfoliative dermatitis), migraine, seizure, transient global amnesia, visual field defect, retinal vein occlusion, retinal artery occlusion, NAION, sudden hearing decrease or loss, priapism
Most common (dose initiation and escalation) Flushing, headache, nausea, vomiting, hypotension, anxiety, chest pain, dizziness, bradycardia, abdominal pain, musculoskeletal pain, dyspnea, tachycardia
Most common (chronic dosing) Headache, jaw pain, flushing, diarrhea, nausea, vomiting, flu-like symptoms, anxiety
Postmarketing Anemia, hypersplenism, pancytopenia, splenomegaly, high output cardiac failure, hyperthyroidism
Pharmacology
PDE5 inhibitor; tadalafil selectively inhibits phosphodiesterase type 5, increasing cGMP concentrations in pulmonary vascular smooth muscle, resulting in relaxation and vasodilation of the pulmonary vascular bed in patients with pulmonary arterial hypertension.
Epoprostenol is a naturally occurring prostacyclin (metabolite of arachidonic acid) that produces direct vasodilation of pulmonary and systemic arterial vascular beds, reducing right- and left-ventricular afterload and increasing cardiac output, and inhibits platelet aggregation.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Tadliq
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (0/12) · Qty limit (9/12)
Veletri
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (0/12) · Qty limit (0/12)
UnitedHealthcare
Tadliq
- Covered on 4 commercial plans
- PA (4/8) · Step Therapy (0/8) · Qty limit (4/8)
Veletri
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Humana
Tadliq
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (3/3) · Qty limit (2/3)
Veletri
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (2/3) · Qty limit (0/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
Cost estimate not availableGood Days: Pulmonary Arterial Hypertension
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Cost estimate not availableAssistance Fund: MPS II- Hunter Syndrome
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
TadliqView full Tadliq profile
VeletriView full Veletri profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.